$8.49
-0.47%
N/A-$0.04
헬스케어
생명공학
NASDAQ
활발히 거래 중
Kyntra Bio, Inc.는 혁신적인 치료제의 초기 발견과 엄격한 개발부터 최종 시장 출시에 이르는 전 과정을 포괄하는 바이오제약 기업으로 기능합니다. 이 회사의 과학적 ...
Kyntra Bio, Inc.는 혁신적인 치료제의 초기 발견과 엄격한 개발부터 최종 시장 출시에 이르는 전 과정을 포괄하는 바이오제약 기업으로 기능합니다. 이 회사의 과학적 ...
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical enterprise dedicated to the discovery, development, and commercialization of groundbreaking treatments for serious unmet medical needs. The company's scientific research delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF), aiming to create therapies for conditions such as anemia, fibrotic disorders, and various forms of cancer. Founded by Thomas B. Neff on September 29, 1993, the company has undergone a significant transformation, rebranding to Kyntra Bio on January 8, 2026, to reflect its renewed focus on oncology and rare disease therapies with potential for outsized impact. Led by CEO Thane Wettig, who has served on the board since April 2010, the company employs 34 full-time staff members. Financially, Kyntra Bio has a market capitalization of approximately $28.7 million, with a current ratio of 3.605 and a working capital of $73.2 million. The company invests heavily in research and development, with R&D expenses representing nearly three times its revenue, and sales and administrative costs over three times revenue. Despite a negative operating cash flow and net loss, the company maintains a cash ratio of 1.316, suggesting sufficient liquidity. The company's pipeline focuses on novel therapies, and its mission is to expand what is possible in treating cancer and rare diseases. Key historical milestones include the approval of roxadustat, a HIF-based therapy, reflecting the vision of founder Thomas Neff. As Kyntra Bio continues to evolve, it remains committed to advancing innovative treatments and making a meaningful impact on patients' lives.